Denosumab

Papers on denosumab

185 papers13 new in 30 days

Sunday, November 15

Thursday, November 12

Journal of Bone Oncology

Calcium, vitamin D not tied to less bone loss on aromatase inhibitors

Over five years, spine bone density fell 11.1% with calcium and vitamin D and 11.4% without supplements in postmenopausal women taking breast cancer hormone therapy.Over five years, spine bone density fell 11.1% with calcium and vitamin D and 11.4% without supplements in postmenopausal women taking breast cancer hormone therapy.

Lumbar vertebrae show similarly sparse internal bone in two sections and a denser network in another, surrounded by faceless women.
Cohort · 636 peopleBone loss

Wednesday, November 11

JAMA Network Open

Bisphosphonates linked to more repeat fractures than denosumab

Women starting bisphosphonates had 52.7 repeat fractures per 1,000 person-years, versus 46.5 with denosumab, during three years of follow-up.Women starting bisphosphonates had 52.7 repeat fractures per 1,000 person-years, versus 46.5 with denosumab, during three years of follow-up.

Forearm bones above small faceless figures contrast a larger fractured bone with a loose fragment against a smaller, intact bone.
Cohort studyBones and joints

Sunday, November 8

Journal of Bone and Mineral Research

Delayed follow-up osteoporosis drugs linked to more hip fractures

Among 8,893 patients, high adherence to teriparatide was linked to a 20% lower relative hip fracture risk than lower adherence.Among 8,893 patients, high adherence to teriparatide was linked to a 20% lower relative hip fracture risk than lower adherence.

An intact upper thigh bone with dense inner struts contrasts with a smaller gray bone with sparse struts and a broken neck, beside upright figures.
Cohort · 8,893 peopleHip fracture

Thursday, November 5

Diabetes & Metabolism

Diabetes risk did not clearly differ between osteoporosis drugs

The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.

Figure from Diabetes & Metabolism

Tuesday, November 3

Monday, November 2

Friday, October 30

Monday, October 26

Friday, October 23

Thursday, October 22

Journal of Cachexia, Sarcopenia and Muscle

Denosumab linked to greater grip strength gains in women

At 12 months, grip strength rose 1.45 kg with denosumab versus 0.66 kg with zoledronic acid in postmenopausal women with osteoporosis.At 12 months, grip strength rose 1.45 kg with denosumab versus 0.66 kg with zoledronic acid in postmenopausal women with osteoporosis.

Study design and multimodal assessment framework.
Cohort · 186 peopleDenosumab

Monday, October 19

Saturday, October 17

Thursday, October 15

Wednesday, October 14

Tuesday, October 6

Monday, September 28

Friday, September 18

Tuesday, September 15

Wednesday, September 9

Tuesday, September 8

Thursday, September 3

Tuesday, September 1

Thursday, August 27

Thursday, August 20

Monday, August 10

Saturday, August 8